After a pilot program last year, the company is launching its Noom Med option – available in 32 states – that will include prescriptions for Ozempic, Wegovy, Mounjaro and other GLP-1 obesity drugs for about $120 a month.

The pharmaceutical company is pushing for fast-track FDA approval of its diabetes drug Mounjaro for obesity today, after releasing promising clinical trial data that validates its claims for weight loss.

Under mounting pressure, Novo Nordisk plans to cut list prices for insulin products by up to 75%, now the latest drugmaker to take such a step following a California lawsuit accusing drugmakers of driving up costs.

As virus rates appear to ebb and companies loosen rules, they could be alienating employees who dutifully got their shots.

For drugmakers, the pandemic has squeezed demand for everything from childhood vaccines to smoking-cessation drugs.

Bogged down by the logistics of testing, employers are favoring lower-cost, easier-to-implement interventions like temperature checks.

Insurers have been experiencing a short-term increase in profits and are passing those savings back.

Software company Practice Fusion was paid by a major opioid manufacturer to design a tool to boost prescriptions.